Review article: Rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 11, 2010, Pages 1155-1164

  Layer, P ^a   Andresen, V ^a  

^a ISRAELITISCHES KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CYTOCHROME P450; LOPERAMIDE; PLACEBO; RIFAXIMIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DISEASE DURATION; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; FLATULENCE; FLUID THERAPY; HEADACHE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; NAUSEA; PRIORITY JOURNAL; PUBLICATION; REVIEW; TENESMUS; TRAVELLER DIARRHEA; VOMITING; WELLBEING;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; ANTIDIARRHEALS; CIPROFLOXACIN; DIARRHEA; HUMANS; LOPERAMIDE; RIFAMYCINS; TRAVEL; TREATMENT OUTCOME;

EID: 77951811277     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04296.x     Document Type: Review

References (50)

1. Al-Abri SS, Breeching NJ, Nye FJ. Traveller's diarrhea. Lancet Infect Dis 2005 5 : 349 360.
2. Steffen R, Collard F, Tornieporth N, et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA 1999 281 : 811 817.
3. Hill DR. Occurrence and self-treatment of diarrhea in a large cohort of Americans travelling to developing countries. Am J Trop Med Hyg 2000 62 : 585 589.
4. Steffen R. Epidemiology of traveler's diarrhea. Clin Infect Dis 2005 41 (Suppl. 8 S536 40.
5. Daniels NA, Neimann J, Karpati A, et al. Traveler's diarrhea at sea: three outbreaks of waterborne enterotoxigenic Escherichia coli on cruise ships. J Infect Dis 2000 181 : 1491 1495.
6. DuPont HL. Systematic review: the epidemiology and clinical features of travellers' diarrhea. Aliment Pharmacol Ther 2009 30 : 187 196.
7. Connor BA. Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome. Clin Infect Dis 2005 41 : S577 86.
8. Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis 2006 43 : 898 901.
9. Adachi JA, Ostrosky-Zeichner L, DuPont HL, Ericsson CD. Empirical antibiotic therapy for traveler's diarrhea. Clin Infect Dis 2000 31 : 1079 1083.
10. Ericsson CD. Travellers' diarrhea. Int J Antimicrob Agents 2003 21 : 116 124.
11. Tribble DR, Sanders JW, Pang LW, et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007 44 : 338 346.
12. Adachi JA, Jiang Z-D, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 2001 32 : 1706 1709.
13. Jiang Z-D, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travellers with diarrhea acquired in Mombasa (Kenya), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002 185 : 497 502.
14. Clarke SC. Diarrheagenic Escherichia coli- an emerging problem? Diagn Microbiol Infect Dis 2001 41 : 93 8.
15. De Bruyn G, Hahn S, Borwick A. Antibiotic treatment for travellers' diarrhea. Cochrane Database Syst Rev 2000 3 : CD002242.
16. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993 328 : 1821 1827.
17. Plaisance KI, Drusano GL, Forrest A, Bustamante CI, Standiford HC. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1987 31 : 956 958.
18. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000 44 : 2600 2603.
19. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 2001 47 (Suppl. 3 9 14.
20. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999 21 : 407 421.
21. Fluoroquinolones: psychiatric adverse effects. Prescrire Int 2008 17 : 20.
22. Committee on Infectious Diseases. Policy statement. The use of systemic fluoroquinolones. Pediatrics 2006 118 : 1287 1292.
23. Pickering LK. Antimicrobial resistance among enteric pathogens. Semin Pediatr Infect Dis 2004 15 : 71 7.
24. Isenbarger DW, Hoge CW, Srijan A, et al. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg Infect Dis 2002 8 : 175 180.
25. Nelson JM, Smith KE, Vugia D, et al. Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J Infect Dis 2004 190 : 1150 1157.
26. Ruiz J, Mensa L, O'Callaghan C, et al. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagn Microbiol Infect Dis 2007 59 : 473 475.
27. Murray BE, Mathewson JJ, DuPont HL, Ericsson CD, Reves RR. Emergence of resistant fecal Escherichia coli in travellers not taking prophylactic antimicrobial agents. Antimicrob Agents Chemother 1990 34 : 515 518.
28. Vila J, Gascon J, Abdalla S, et al. Antimicrobial resistance of Shigella isolates causing traveler's diarrhea. Antimicrob Agents Chemother 1994 38 : 2668 2670.
29. Sanches Ito CA, Gales AC, Tognim MCB, Munerato P, Dalla Costa LM. Quinolone-resistant Escherichia coli. Braz J Infect Dis 2008 12 : 5 9.
30. Sierra JM, Ruiz J, Navia MM, Vargas M, Gascon J, Vila J. In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob Agents Chemother 2001 45 : 643 644.
31. DuPont HL, Jiang Z-D, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind trial. Clin Infect Dis 2001 33 : 1807 1815.
32. Gomi H, Jiang Z-D, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001 45 : 212 216.
33. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007 51 : 2716 2719.
34. Rizzello F, Gionchetti P, Venturi A, et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998 54 : 91 3.
35. De LeoC, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986 12 : 979 981.
36. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000 46 : 253 266.
37. DuPont HL. Systematic review: prevention of travellers' diarrhea. Aliment Pharmacol Ther 2008 27 : 741 751.
38. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of traveler's diarrhea. Digestion 1998 59 : 708 714.
39. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003 98 : 1073 1078.
40. Infante RM, Ericsson CD, Jiang Z-D, et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2004 2 : 135 138.
41. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of traveler's diarrhea. Am J Trop Med Hyg 2006 74 : 1060 1066.
42. DuPont HL, Haake R, Taylor DN, et al. Rifaximin treatment of pathogen-negative traveler's diarrhea. J Travel Med 2007 14 : 16 9.
43. DuPont HL, Jiang ZD, Belkind-Gerson J, et al. Treatment of traveler's diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007 5 : 451 456.
44. DuPont HL, Jiang Z-D, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent traveler's diarrhea. Ann Intern Med 2005 142 : 805 812.
45. DuPont HL, Ericsson CD, de la Cabada FJ, et al. Prevention of travelers' diarrhea with rifaximin - a phase 3 randomized double-blind placebo-controlled trial in U.S. students in Mexico. Am J Gastroenterol 2006 101 (Suppl. 2 S197.
46. DuPont HL, Jiang Z-D. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004 10 : 1009 1011.
47. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharm Res 1994 14 : 51 6.
48. Jiang Z-D, Ke S, Palazzini E, Riopel L, DuPont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000 44 : 2205 2206.
49. Braun Trapnell C, Connolly M, Pentikis H, Forbes B, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics or ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007 41 : 222 228. (Pubitemid 46340052)
50. Pentikis HS, Connolly M, Trapnell CB, Forbes WP, Bettenhausen DK. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007 27 : 1361 1369. (Pubitemid 47530442)